Key takeaways
- Healthcare is the highest-stakes category in AI search. ChatGPT and Google AI Overviews both treat it as YMYL, so they lean on a small set of sources they consider safe.
- Promptwatch Data for Sep 9 to Oct 8, 2026 shows NIH alone takes 5.46% of ChatGPT healthcare citations, more than the FDA, NHS, CMS and SAMHSA combined. Brand sites are fighting for crumbs.
- A visibility score is not enough in pharma. You need claim-level monitoring (what AI says about your drug), citation tracing, audit trails and approval workflows.
- Build the prompt set with your medical team, in patient and HCP language, and keep it fixed so medical, legal and regulatory (MLR) can review trends.
- You cannot edit an AI answer. You can fix the sources it learns from, so the work is correcting your own pages and earning citations from guideline bodies, journals and associations.
Why healthcare and pharma are a different problem
Most AI visibility advice is written for SaaS and e-commerce. Healthcare breaks those playbooks in three ways.
First, the models are conservative. A WG Content review of hundreds of AI-generated healthcare answers found the systems build responses around a small set of sources they treat as safe. That matches what the citation data shows, and it means a brand with perfect SEO can still be absent.
Second, the cost of a wrong answer is not a lost click. If ChatGPT states a wrong dosage, an outdated indication or a made-up side effect about your product, that is a patient safety and pharmacovigilance question, not a marketing metric.
Third, you operate under review. Anything you publish to influence AI answers passes through medical, legal and regulatory sign-off, and monitoring itself may need to be documented. Tools built for fast-moving DTC brands often have no concept of this.
Demand is real. A SearchEye write-up cites an Ipsos survey where 31% of consumers used generative AI for health information between doctor visits, but only 38% somewhat or generally trusted it. SearchEye sells a competing product, so treat its framing with care, but the usage-versus-trust gap is a fair way to describe why accuracy and source transparency are buying requirements here and not nice-to-haves.
What the citation data says about who AI trusts
Before you evaluate any tool, look at who actually gets cited. Promptwatch's report on most cited sites in ChatGPT for healthcare prompts covers organic healthcare prompts from Sep 9 to Oct 8, 2026:
- nih.gov holds 5.46% of all healthcare citations across six subdomains. PubMed Central has 2.38% and PubMed 2.33%.
- The FDA has 1.76% (including its drug database on accessdata.fda.gov) and the NHS 1.1%.
- Government and public health sites earn 7.06% of all healthcare citations, medical associations 1.39%, hospitals and clinics 0.89%, and reviews and directories 0.46%.
- The top non-government names are the American Society of Plastic Surgeons (0.64%), the American Academy of Dermatology (0.54%), Mayo Clinic (0.49%) and Cleveland Clinic (0.4%).
- Boots is the only pharmacy in the chart, at 0.28%.
The twenty top domains together hold only 15.54% of healthcare citations, so the long tail is large. Still, a pharma manufacturer's own site does not appear among the leaders. For a brand team that is the uncomfortable finding: AI mostly answers health questions from regulators, research databases and professional bodies, and your brand shows up when those sources talk about you.
That shapes the strategy. Back claims with peer-reviewed studies linked on PubMed or PubMed Central. Make pages agree with FDA, CDC, NHS and NICE guidance and link to it. Work with medical associations in your specialty (the AAD and ASPS together earn 1.18%, more than Mayo Clinic and Cleveland Clinic combined). Keep Doctify and WebMD doctor profiles complete, since they are the only directory sites in the chart at 0.23% each.
The broader pattern is also worth knowing. Promptwatch's data on ChatGPT citation share by domain rank shows mid-authority sites (DR 46-75) earning almost half of citations in August 2026, so a specialist society or niche clinical publisher can outperform a giant. And the half-life report found landing pages and docs stay cited longest while news loses half its pages within 36 days, which argues for durable, reviewed reference pages over reactive posts.
What YMYL changes about prompt monitoring
Build the prompt set with your medical team
The Get3rd guide to pharma AI visibility gets one thing right: write prompts the way patients and HCPs ask, not the way your brand team talks. Nobody types your tagline. They type "is [drug] safe with alcohol", "alternatives to [drug] for migraines", or "what are the side effects of [class] drugs".
Split the set into groups:
- Branded safety and efficacy questions (highest risk, review weekly)
- Condition and symptom questions where you want to be a named option
- Comparison and "best of" prompts at decision stage
- HCP-style prompts about mechanism, dosing and trial data
WG Content makes a useful point on coverage: check whether you show up only in basic definitions or also in comparison and decision-stage prompts. Appearing in the glossary-level answers and vanishing in the decision stage is common.
Lock the prompt wording once MLR agrees to it. Changing prompts midstream makes trend lines meaningless, and reviewers will ask why numbers moved.
Track personas and locations separately
A patient, a caregiver and a cardiologist get different answers. Regulations also differ by country, and the label for the same drug can differ between the US and the EU. Pick a tool where each monitor is fixed to one language and country so markets do not blur together. Promptwatch does this through monitors and custom personas, with persona radar views that show where one audience gets a worse answer than another.
Monitor claims, not just mentions
A mention count says almost nothing in pharma. What matters is the statement. Is AI saying your product is approved for an indication it is not? Is it quoting a withdrawn warning? Is it recommending a competitor for the wrong reason?
Look for claim extraction and accuracy checking. Promptwatch's Brand Narrative pulls the individual claims AI makes about you and competitors out of tracked responses and groups them by theme, and Fact Check (Business tier and above) lets you mark a claim accurate or inaccurate and then finds the pages on your own site that state it or its opposite. That last step matters: it tells you whether AI learned the error from your own outdated PDF.
Know the limits
Qvery's FAQ makes a blunt point: you cannot fix a wrong answer by editing it, and OpenAI itself warns that search results and citations can be incomplete or incorrect. A tool cannot correct a model. It can show you the error, the sources behind it, and where to intervene. Anyone selling guaranteed corrections is overselling.
What to require from an enterprise tool
Here is the checklist I would hand to a regulatory affairs lead and a procurement team.
| Requirement | Why it matters in healthcare |
|---|---|
| Real interface data, not only APIs | Consumer answers and citations can differ from API output, and consumers use the interface |
| Claim-level analysis and fact checking | Safety and label accuracy are the real risk |
| Citation and source tracing | You need to see which journals, regulators or forums shaped an answer |
| Locale and persona separation | Labels, regulations and patient vs HCP language differ |
| Audit log, roles, SSO | Compliance teams need to see who changed what |
| Security certifications | ISO/IEC 27001 and GDPR matter in procurement |
| Crawler logs | Tells you whether AI bots can read your reviewed content at all |
| Approval workflow for content | Nothing ships without MLR sign-off |
| Export and reporting | Evidence for internal and regulatory stakeholders |
Privacy cuts the other way too. Some vendors, such as PromptRush, state they track only publicly available AI answers. That is the right posture: your monitoring should never involve entering patient data or real adverse event reports into any tool.
Tools worth evaluating
The field is crowded, and I have not run pricing or feature comparisons for every enterprise vendor, so treat this as a shortlist rather than a ranking.
Promptwatch
For teams that want monitoring and a way to act on it in one place, Promptwatch is the platform I would start with. It tracks ChatGPT, Gemini, Claude, Perplexity, Google AI Overviews, AI Mode, Copilot and others through their real interfaces by country and language, then traces citations, shows IP-verified AI crawler logs, and ties changes to AI-referred traffic. The Action Board prioritises fixes, and the Content Agent can draft and publish pages to WordPress, Webflow or Framer, with a review inbox so nothing goes live unapproved. For regulated teams the relevant details are Fact Check, the audit log (Business and above), SSO on Enterprise, and ISO/IEC 27001 certification with EU-based data handling.
Pricing starts at $95 per month (Essential), but the features healthcare teams usually want, Fact Check, the audit log, Content Agent and state/city tracking, begin on Business at $579 per month. Confirm current numbers at promptwatch.com/pricing. A 7-day free trial and a free AI visibility report are the low-risk starting points. If your team keeps asking "which of our pages is teaching the model the wrong thing", read how it compares in Promptwatch vs Profound.
Profound
SearchEye's roundup lists Profound as a strong fit for regulated enterprises needing governance and security controls, with tracking across citations, sentiment, competitors, personas, regions and prompt-level results. Its listed downsides are a steep learning curve and the fact that finding a gap does not by itself resolve the content problem. That second point is the one to test in a demo.
Peec AI
Peec AI is described in that same roundup as the better choice for analytics depth across models and countries. A good fit if your need is multi-market reporting and your content work happens elsewhere.
Enterprise SEO suites
If you already run BrightEdge, Conductor or seoClarity, check their AI modules first, since procurement and security review may already be done. BrightEdge has published research on the safety signals that trigger brand criticism in YMYL search, which is relevant background for anyone setting sentiment alerts.
The usual tradeoff applies: suite modules tend to cover fixed prompt sets and shallower AI-specific data than dedicated platforms.
Other names that came up
Brandlight positions itself as an enterprise AI visibility operating system, and Scrunch AI covers monitoring for brands and agencies.
For a wider scan, the GEO software directory at bestgeosoftware.com lists far more options than fit in one guide.
Comparison at a glance
| Tool | Strength for healthcare | Watch out for |
|---|---|---|
| Promptwatch | Monitoring plus claim checking, crawler logs and content publishing with review | Best regulated features sit on Business and Enterprise |
| Profound | Governance and security focus, per SearchEye | Learning curve; gap finding is not the fix |
| Peec AI | Cross-model and cross-country analytics | Primarily monitoring |
| BrightEdge, Conductor, seoClarity | Fits existing enterprise procurement | AI data can be shallower |
A monitoring workflow that survives MLR review
- Agree scope with medical, legal and regulatory: which products, which markets, which prompt categories. Record it.
- Build and freeze the prompt set in patient and HCP language. Tag prompts by risk level.
- Set a baseline across models and countries before changing anything.
- Review claims weekly for safety-relevant prompts. Mark inaccurate statements and log them.
- Trace each error to a source. Is it your own page, a stale third-party listing, a forum thread, or a model with old training data?
- Fix what you control: update pages, add references to PubMed and regulator guidance, check that AI crawlers can read the corrected version.
- Route anything that looks like an adverse event or safety signal through your pharmacovigilance process, not the marketing tool.
- Re-measure after the next crawl and report to stakeholders with the same prompts as the baseline.
Varn Health frames its framework around benchmarking visibility and accuracy to find risks, gaps and missed opportunities. That pairing, visibility and accuracy together, is the right mental model.
Content strategy under citation risk
Because AI favors regulators and research databases, your own site works best as the clear, verifiable source those bodies would agree with. A few practical rules:
- Every clinical claim links to a primary source. Not a blog about the study.
- Keep indications, dosing and warnings consistent across every page, PDF and microsite. Inconsistency is how models pick up the wrong version.
- Retire or redirect old pages. A discontinued label sitting live is a liability.
- Publish durable reference pages (condition guides, drug information, FAQs) instead of news-style posts that lose citations fast.
- Make sure AI crawlers can reach approved content. Crawler logs will tell you whether bots are hitting errors or never arriving.
- Give specialist societies and key opinion leaders accurate material. Their pages are the ones AI is likely to cite.
A ChatGPT-focused view is useful here as well, since Promptwatch's data on content types shows product pages at 22.4% of citations (Sep 28 to Oct 4, 2026). For a pharma brand, a well-structured, reviewed product information page is a legitimate lever, though how much freedom you have depends on promotional rules in each market.
What I would do first
Pick one product and one market. Build 30 to 50 prompts with your medical team, run a baseline, and read the actual answers rather than the dashboard. In my experience the first review is the sobering one: you see which regulator or association answers on your behalf, and whether the claims match your label. Then decide whether you need a monitoring-only tool or a platform that also helps you fix and publish. If the answer is the latter, a trial of Promptwatch against one or two enterprise alternatives, with your regulatory team in the room, will show quickly which one fits your review process.
If you want an outside team to run this alongside your internal reviewers, 1001 SEO Media works on AI search and GEO programs, and it uses Promptwatch as its visibility platform. Either way, keep the prompt set frozen, the claims logged and the fixes tied to sources you can cite.